Hypermethylation of a Small CpGuanine-Rich Region Correlates with Loss of Activator Protein-2α Expression during Progression of Breast Cancer

The transcription factor activator protein-2α (AP-2α) has recently been implicated as a tumor suppressor protein that can be lost during tumor progression and that exhibits growth-inhibitory properties when overexpressed in cancer cell lines. We now demonstrate that hypermethylation of a discrete 5′ region within a promoter CpG island of the gene is associated in breast cancer with the loss of AP-2α expression. Multiple CpG sites within the island become hypermethylated during breast cancer evolution. However, only hypermethylation of the most CpG-rich region, a small, ∼300-bp area at the 3′ end of exon 1, fully distinguishes neoplastic from normal breast tissue and correlates with transcriptional silencing. In cell culture, silenced AP-2α, associated with exon 1 hypermethylation, is re-expressed by 5-aza-2′deoxycytidine resulting in the restoration of a functional DNA sequence-specific binding protein. In vivo, as detected by a very sensitive nested PCR approach, methylation of the discrete AP-2α exon 1 region does not occur in normal breast epithelium and occurs in only 3 (16%) of 19 ductal carcinoma in situ (DCIS) lesions, but is present in 12 (75%) of 16 invasive breast tumors (P < 0.001; DCIS versus invasive cancers). Tumors unmethylated for this region expressed AP-2α protein throughout, whereas tumors with hypermethylation showed large areas of loss. Our studies then determine that hypermethylation of a small region of a CpG island correlates with silencing of AP-2α in breast cancer and suggest that inactivation of this gene could be a factor in, and a useful marker for, the progression of DCIS lesions.

[1]  J. Herman,et al.  GATA-4 and GATA-5 Transcription Factor Genes and Potential Downstream Antitumor Target Genes Are Epigenetically Silenced in Colorectal and Gastric Cancer , 2003, Molecular and Cellular Biology.

[2]  E. Knapik,et al.  Noradrenergic neurons in the zebrafish hindbrain are induced by retinoic acid and require tfap2a for expression of the neurotransmitter phenotype , 2003, Development.

[3]  Minoru Toyota,et al.  Aberrant Promoter Methylation of the Transcription Factor Genes PAX5 α and β in Human Cancers , 2003 .

[4]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[5]  A. Bird DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[6]  P. Troncoso,et al.  Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  G. Berx,et al.  The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. , 2001, Molecular cell.

[8]  J. Herman,et al.  SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity , 2001, Nature Genetics.

[9]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[10]  J. Herman,et al.  p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. , 2001, Cancer research.

[11]  Hoguen Kim,et al.  Identification of novel deletion regions on chromosome arms 2q and 6p in breast carcinomas by amplotype analysis , 2001, Genes, chromosomes & cancer.

[12]  R. Buettner,et al.  Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. , 2000, Gene.

[13]  J. Herman,et al.  Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.

[14]  J. Herman,et al.  Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. , 2000, Cancer research.

[15]  A. Mannermaa,et al.  Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2 α in cutaneous melanoma , 2000, British Journal of Cancer.

[16]  V. Kosma,et al.  Expression of transcription factor AP-2α predicts survival in epithelial ovarian cancer , 2000, British Journal of Cancer.

[17]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[18]  V. Kosma,et al.  Expression of Activator Protein 2 in Prostate Cancer Is Related to Tumor Differentiation and Cell Proliferation , 2000, European Urology.

[19]  A. G. Herreros,et al.  The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells , 2000, Nature Cell Biology.

[20]  J. Herman,et al.  Methylation Patterns of the E-cadherin 5′ CpG Island Are Unstable and Reflect the Dynamic, Heterogeneous Loss of E-cadherin Expression during Metastatic Progression* , 2000, The Journal of Biological Chemistry.

[21]  I. Ellis,et al.  Immunohistochemical analysis reveals a tumour suppressor‐like role for the transcription factor AP‐2 in invasive breast cancer , 1999, The Journal of pathology.

[22]  Lisa A. McPherson,et al.  AP2alpha and AP2gamma: a comparison of binding site specificity and trans-activation of the estrogen receptor promoter and single site promoter constructs. , 1999, Nucleic acids research.

[23]  J. Herman,et al.  Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. , 1999, Blood.

[24]  F. Hanaoka,et al.  Distribution of AP-2 subtypes in the adult mouse brain , 1999, Neuroscience Research.

[25]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[26]  P. Glazer,et al.  Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. , 1998, Cancer research.

[27]  V. Kosma,et al.  Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  F. Hanaoka,et al.  A novel alternative spliced variant of the transcription factor AP2alpha is expressed in the murine ocular lens. , 1998, Developmental biology.

[29]  C. Muchardt,et al.  RB and c-Myc Activate Expression of the E-Cadherin Gene in Epithelial Cells through Interaction with Transcription Factor AP-2 , 1998, Molecular and Cellular Biology.

[30]  J. Herman,et al.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Herman,et al.  Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. , 1998, Cancer research.

[32]  Stephen B. Baylin,et al.  Mapping Patterns of CpG Island Methylation in Normal and Neoplastic Cells Implicates Both Upstream and Downstream Regions inde Novo Methylation* , 1997, The Journal of Biological Chemistry.

[33]  W. El-Deiry,et al.  AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression , 1997, Nature Genetics.

[34]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. McMahon,et al.  Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2 , 1996, Nature.

[36]  R. Jaenisch,et al.  Transcription factor AP-2 essential for cranial closure and craniofacial development , 1996, Nature.

[37]  P. Mitchell,et al.  Alternative mRNAs encode multiple isoforms of transcription factor AP-2 during murine embryogenesis. , 1995, Developmental biology.

[38]  M. Sarkiss,et al.  N-ras oncogene causes AP-2 transcriptional self-interference, which leads to transformation. , 1994, Genes & development.

[39]  J. Wahlfors,et al.  Automated fluorescent genomic sequencing as applied to the methylation analysis of the human ornithine decarboxylase gene. , 1994, DNA sequence : the journal of DNA sequencing and mapping.

[40]  R. Glockshuber,et al.  An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2 , 1993, Molecular and cellular biology.

[41]  S. Weitzman,et al.  Culture of normal and malignant primary human mammary epithelial cells in a physiological manner simulates in vivo growth patterns and allows discrimination of cell type. , 1993, Cancer research.

[42]  R. Tjian,et al.  Transcription factor AP-2 is expressed in neural crest cell lineages during mouse embryogenesis. , 1991, Genes & development.

[43]  R. Tjian,et al.  Positive and negative regulation of transcription in vitro: Enhancer-binding protein AP-2 is inhibited by SV40 T antigen , 1987, Cell.